Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003637547 | SCV004554091 | uncertain significance | Fanconi anemia | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 198 of the FANCL protein (p.Lys198Asn). This variant is present in population databases (rs755792621, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with FANCL-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FANCL protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004621891 | SCV005113460 | uncertain significance | Inborn genetic diseases | 2024-05-15 | criteria provided, single submitter | clinical testing | The c.594G>C (p.K198N) alteration is located in exon 8 (coding exon 8) of the FANCL gene. This alteration results from a G to C substitution at nucleotide position 594, causing the lysine (K) at amino acid position 198 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005038501 | SCV005658691 | uncertain significance | Fanconi anemia complementation group L | 2024-02-23 | criteria provided, single submitter | clinical testing |